Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age14+
SponsorInmunotek S.L.
About this trial
Observational study to evaluate the safety of immunotherapy as a treatment for Hymenoptera venom allergy, analyzing the adverse reaction to immunotherapy as well as the allergic reaction to a spontaneous hymenoptera sting. This study will be conducted in Spain (multicentric) and data will be collected prospectively.
Eligibility criteria
Qualifiers
The study population consisted of allergic participants indicated for treatment with immunotherapy with hymenoptera venom (Apis mellifera or Vespula spp.) according to standard clinical practice.
Age equal to or older than 14 years, without gender differences.
Not having received immunotherapy with hymenoptera venom in the previous 5 years.
That they agree to participate in the study and sign the informed consent form. In the case of minors, the parent or guardian of the participant must also sign the informed consent form.
Disqualifiers
Pregnant or breastfeeding women.
Having received immunotherapy with hymenoptera venom during the 5 years prior to the start of the study.
Participants who do not agree to participate and/or do not sign the informed consent form.
Participants who do not comply with the medical indications or do not show cooperation with respect to the immunotherapy treatment.
Trial design
Treatments tested in this trial
- VENOX
Treatment groups
120 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov